Key Takeaways
- In 2022, an estimated 2.7 million people aged 12 or older in the U.S. reported past-year methamphetamine use, representing 0.9% of the population
- Past-month methamphetamine use among U.S. adults aged 18-25 increased by 50% from 2015 to 2019, rising from 0.5% to 0.8% prevalence
- In 2021, methamphetamine was involved in 36,000 overdose deaths in the U.S., a 50% increase from 2020, often polydrug with fentanyl
- In 2022, methamphetamine caused severe skin damage in 45% of chronic users seeking ER care in Texas
- Chronic meth use leads to 30-50% reduction in dopamine transporter density in brain scans of users
- Methamphetamine users have 4.7 times higher risk of Parkinson's disease per 10-year study
- Meth users aged 18-34 have 11% white adult U.S. population share but 26% of meth deaths
- Among U.S. meth overdose deaths in 2021, 70% were male
- Native Americans/Alaska Natives had meth use disorder rate 3x national average in 2021
- Methamphetamine use costs U.S. economy $23.4 billion annually in healthcare 2021 est.
- Lost productivity from meth use disorder totals $12 billion yearly in U.S., 2022 data
- Criminal justice costs for meth-related offenses reached $8.5 billion in 2020
- Only 18% of meth use disorder patients achieve long-term remission after treatment
- Contingency management therapy shows 60% abstinence rate at 6 months for meth users
- In 2022, 1.2 million Americans received treatment for meth use disorder
Methamphetamine use is rising, causing more overdoses, severe health damage, and costing the U.S. billions.
Demographics and Population Trends
Demographics and Population Trends Interpretation
Economic and Social Costs
Economic and Social Costs Interpretation
Health and Medical Effects
Health and Medical Effects Interpretation
Prevalence and Usage Statistics
Prevalence and Usage Statistics Interpretation
Treatment, Recovery, and Policy Outcomes
Treatment, Recovery, and Policy Outcomes Interpretation
Sources & References
- Reference 1SAMHSAsamhsa.govVisit source
- Reference 2NIDAnida.nih.govVisit source
- Reference 3CDCcdc.govVisit source
- Reference 4DRUGABUSEdrugabuse.govVisit source
- Reference 5NCBIncbi.nlm.nih.govVisit source
- Reference 6MONITORINGTHEFUTUREmonitoringthefuture.orgVisit source
- Reference 7DEAdea.govVisit source
- Reference 8DRUGABUSESTATISTICSdrugabusestatistics.orgVisit source
- Reference 9NIHnih.govVisit source
- Reference 10AJPHajph.aphapublications.orgVisit source
- Reference 11EPAepa.govVisit source
- Reference 12NEJMnejm.orgVisit source
- Reference 13AHAJOURNALSahajournals.orgVisit source
- Reference 14NATUREnature.comVisit source
- Reference 15JAMANETWORKjamanetwork.comVisit source
- Reference 16SLEEPFOUNDATIONsleepfoundation.orgVisit source
- Reference 17PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 18JNEUROSCIjneurosci.orgVisit source
- Reference 19ACPJOURNALSacpjournals.orgVisit source
- Reference 20PSYCHIATRYpsychiatry.orgVisit source
- Reference 21BIOLOGICALPSYCHIATRYJOURNALbiologicalpsychiatryjournal.comVisit source
- Reference 22WWWDASISwwwdasis.samhsa.govVisit source
- Reference 23THETREVORPROJECTthetrevorproject.orgVisit source
- Reference 24BLSbls.govVisit source
- Reference 25CHILDWELFAREchildwelfare.govVisit source
- Reference 26FMCSAfmcsa.dot.govVisit source
- Reference 27BJSbjs.ojp.govVisit source
- Reference 28RANDrand.orgVisit source
- Reference 29URBANurban.orgVisit source
- Reference 30ACFacf.hhs.govVisit source
- Reference 31HCUP-UShcup-us.ahrq.govVisit source
- Reference 32NCJRSncjrs.govVisit source
- Reference 33ASPEaspe.hhs.govVisit source
- Reference 34HEALTHAFFAIRShealthaffairs.orgVisit source
- Reference 35NBERnber.orgVisit source
- Reference 36NSCnsc.orgVisit source
- Reference 37ENDHOMELESSNESSendhomelessness.orgVisit source
- Reference 38NHTSAnhtsa.govVisit source
- Reference 39GAOgao.govVisit source
- Reference 40EDed.govVisit source
- Reference 41JAMAPSYCHIATRYjamapsychiatry.comVisit source
- Reference 42AAaa.orgVisit source
- Reference 43DOLdol.govVisit source
- Reference 44OREGONoregon.govVisit source






